130 related articles for article (PubMed ID: 38847136)
1. Rapid rituximab administration: Safety of 60-minute infusions in malignant and benign haematological disease.
Whiting R; Misko J; McGuire M; Fox E
J Oncol Pharm Pract; 2024 Jun; ():10781552241260863. PubMed ID: 38847136
[TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
3. Sixty-minute infusion rituximab protocol allows for safe and efficient workflow.
Dotson E; Crawford B; Phillips G; Jones J
Support Care Cancer; 2016 Mar; 24(3):1125-9. PubMed ID: 26268782
[TBL] [Abstract][Full Text] [Related]
4. Rapid infusion rituximab changing practice for patient care.
Al Zahrani A; Ibrahim N; Al Eid A
J Oncol Pharm Pract; 2009 Sep; 15(3):183-6. PubMed ID: 19171551
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of a 90-minute rapid infusion of Sandoz biosimilar rituximab in B-cell lymphoproliferative disorders in a real-world setting.
Muntañola A; Arguiñano-Pérez JM; Dávila J; de Villambrosia SG; Carpio C; Jiménez-Ubieto A; Salar A;
Clin Transl Sci; 2023 Feb; 16(2):305-312. PubMed ID: 36385738
[TBL] [Abstract][Full Text] [Related]
6. Rapid-infusion rituximab in lymphoma treatment: 2-year experience in a single institution.
Atay S; Barista I; Gundogdu F; Akgedik K; Arpaci A
J Oncol Pract; 2012 May; 8(3):141-3. PubMed ID: 22942806
[TBL] [Abstract][Full Text] [Related]
7. Rapid rituximab infusion, local center experience.
Monem EA; Al-Bahrani B; Mehdi I; Nada A
Gulf J Oncolog; 2013 Jul; 1(14):52-6. PubMed ID: 23996867
[TBL] [Abstract][Full Text] [Related]
8. Acute adverse reactions of rapid Rituximab infusion among adult patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
Lang D; George C
JBI Libr Syst Rev; 2011; 9(1):1-30. PubMed ID: 27819968
[TBL] [Abstract][Full Text] [Related]
9. Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: a single-centre experience.
Can M; Alibaz-Öner F; Yılmaz-Öner S; Atagündüz P; İnanç N; Direskeneli H
Clin Rheumatol; 2013 Jan; 32(1):87-90. PubMed ID: 23053686
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of non-initial rapid infusion of rituximab plus chemotherapy in Chinese patients with CD20+ non-Hodgkin's lymphoma.
Zhao W; Gao Y; Bai B; Cai QC; Wang XX; Cai QQ; Huang HQ
Expert Opin Drug Saf; 2015 Jan; 14(1):21-9. PubMed ID: 25412839
[TBL] [Abstract][Full Text] [Related]
11. Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma.
Modelevsky L; Tizon R; Reiss SN; Smith M; Garonce R; Kaley T
CNS Oncol; 2018 Jul; 7(3):CNS19. PubMed ID: 30221993
[TBL] [Abstract][Full Text] [Related]
12. Rapid-Infusion Rituximab in a Pediatric Population.
Gaffney KJ; Dahl EM; Stanton MP; Starek E; Zembillas AS
J Pediatr Pharmacol Ther; 2020; 25(3):215-219. PubMed ID: 32265604
[TBL] [Abstract][Full Text] [Related]
13. [Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia].
Šimkovič M; Vodárek P; Motyčková M; Žák P; Smolej L
Vnitr Lek; 2015; 61(7-8):626-32. PubMed ID: 26375688
[TBL] [Abstract][Full Text] [Related]
14. A prospective study to evaluate the feasibility and economic benefits of rapid infusion rituximab at an Asian cancer center.
Chiang J; Chan A; Shih V; Hee SW; Tao M; Lim ST
Int J Hematol; 2010 Jun; 91(5):826-30. PubMed ID: 20461562
[TBL] [Abstract][Full Text] [Related]
15. Implementation of an Accelerated Infusion Protocol (90-Minute Infusion) of Rituximab and Its Safety in Patients With Autoimmune Rheumatic Diseases at a Tertiary Veterans Affairs Center.
Nahra V; Panning D; Anthony D; Mattar M
Cureus; 2024 May; 16(5):e60558. PubMed ID: 38887351
[TBL] [Abstract][Full Text] [Related]
16. Rapid infusion of rituximab over 60 min.
Tuthill M; Crook T; Corbet T; King J; Webb A
Eur J Haematol; 2009 Apr; 82(4):322-5. PubMed ID: 19220420
[TBL] [Abstract][Full Text] [Related]
17. Rapid rituximab infusion is safe and well tolerated in malignant and benign disease.
Ursu SG; Rinchuse DL; Lister J
J Oncol Pharm Pract; 2021 Dec; 27(8):1919-1922. PubMed ID: 33287667
[TBL] [Abstract][Full Text] [Related]
18. Peri-infusional adverse reactions to rituximab in patients with non-Hodgkin's lymphoma.
Arredondo-Garza T; Majluf-Cruz A; Vela-Ojeda J; Mariscal-Ramírez I; Solis-Anaya L; Lopez-Gutiérrez JR; Guadarrama CH; Rico-Curiel E; Armenta-San Sebastián JA; Castañeda-Hernández G
Arch Med Res; 2013 Oct; 44(7):549-54. PubMed ID: 24120421
[TBL] [Abstract][Full Text] [Related]
19. Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre.
Brown BA; Torabi M
Drug Saf; 2011 Feb; 34(2):117-23. PubMed ID: 21247220
[TBL] [Abstract][Full Text] [Related]
20. Use of a pharmacy protocol to convert standard rituximab infusions to rapid infusion shortens outpatient infusion clinic visits.
Swan JT; Zaghloul HA; Cox JE; Murillo JR
Pharmacotherapy; 2014 Jul; 34(7):686-94. PubMed ID: 24706572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
